Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 3/20 | 0.41 |
| ▸ | ERBB2 known ✓ | P04626 | 1/20 | 0.34 |
| ▸ | CHRNB2 known ✓ | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 known ✓ | P43681 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3018038 | 1.00 | EGFR (0.41) | EGFRCYP1A2CYP2C9HTTRAB9A | |
| SCHEMBL3022216 | 0.85 | ROCK2 (0.41) | EGFRCYP1A2CYP2C9RAB9ACYP2D6 | |
| SCHEMBL3022211 | 0.85 | ROCK2 (0.41) | EGFRCYP1A2CYP2C9RAB9ACYP2D6 | |
| SCHEMBL3012153 | 0.84 | CHRNB2 (0.53) | CYP1A2CYP2C9HTTCYP2D6CYP2C19 | |
| SCHEMBL7941619 | 0.84 | CHRNB2 (0.53) | CYP1A2CYP2C9HTTCYP2D6CYP2C19 | |
| SCHEMBL7941626 | 0.84 | CHRNB2 (0.53) | CYP1A2CYP2C9HTTCYP2D6CYP2C19 | |
| SCHEMBL3015439 | 0.84 | CHRNB2 (0.53) | CYP1A2CYP2C9HTTCYP2D6CYP2C19 | |
| SCHEMBL3015444 | 0.84 | CHRNB2 (0.53) | CYP1A2CYP2C9HTTCYP2D6CYP2C19 | |
| SCHEMBL3012159 | 0.84 | CHRNB2 (0.53) | CYP1A2CYP2C9HTTCYP2D6CYP2C19 | |
| SCHEMBL3016752 | 0.83 | CHRNB2 (0.43) | HTTSMN1; SMN2KDM4EMAPTCHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288420-B2 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2253616-A1 | Process for the preparation of compounds capable of activating cholinergic receptors | Targacept, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7790757-B2 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100222395-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100204481-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100160390-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100121061-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20080214628-A1 | Compounds Capable of Activating Cholinergic Receptors | CALDWELL WILLIAM SCOTT | 2008-09-04 | — | — | US | disclosed |
| US-20080139809-A1 | Compounds Capable of Activating Cholinergic Receptors | CALDWELL WILLIAM SCOTT | 2008-06-12 | — | — | US | disclosed |
| US-7307092-B2 | Compounds Capable of Activating Cholinergic Receptors | TARGACEPT, INC. (US) | 2007-12-11 | — | — | US | disclosed |
| US-20050131034-A1 | Compounds capable of activating cholinergic receptors | CALDWELL WILLIAM S (US) | 2005-06-16 | — | — | US | disclosed |
| EP-1086082-B9 | ARYLSUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS | TARGACEPT INC (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20040214835-A1 | Compounds capable of activating cholinergic receptors | CALDWELL WILLIAM SCOTT (US) | 2004-10-28 | — | — | US | disclosed |
| EP-1086082-B1 | ARYLSUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS | TARGACEPT INC (US) | 2004-08-18 | — | — | EP | disclosed |
| WO-2004031151-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2004-04-15 | — | — | WO | disclosed |
| US-20030125345-A1 | Nicotinic compounds; treating central nervous system disorders | TARGACEPT, INC. | 2003-07-03 | — | — | US | disclosed |
| US-20020052497-A1 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. | 2002-05-02 | — | — | US | disclosed |
| US-6232316-B1 | SUCH AS PARKINSON'S DISEASE, TOURETTE'S SYNDROME, SCHIZOPHRENIA, AND SENILE DEMENTIA OF ALZHEIMERS DISEASE | TARGACEPT, INC. | 2001-05-15 | — | — | US | disclosed |
| EP-1086082-A1 | ARYLSUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS | R.J. REYNOLDS TOBACCO COMPANY (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999065876-A1 | ARYL SUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052497-A1 | Compounds capable of activating cholinergic receptors | CHRNA4, CHRNB4, CHRM4 | EGFR 811/4885ERBB2 340/4885CHRNB2 4/4885 |
| US-20100222395-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | CHRNA4, CHRNB4, CHRM4 | EGFR 811/4885ERBB2 340/4885CHRNB2 4/4885 |
| US-20050131034-A1 | Compounds capable of activating cholinergic receptors | CHRNA4, CHRNB4, CHRM4 | EGFR 760/4885ERBB2 317/4885CHRNB2 4/4885 |
| US-20100204481-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | CHRNA4, CHRNB4, CHRM4 | EGFR 811/4885ERBB2 340/4885CHRNB2 4/4885 |
| US-20030125345-A1 | Nicotinic compounds; treating central nervous system disorders | SLC6A2, CHRNA6, CHRNA10 | EGFR 3706/4885ERBB2 2548/4885CHRNB2 9/4885 |
| US-20080139809-A1 | Compounds Capable of Activating Cholinergic Receptors | CHRNA4, CHRNB4, CHRM4 | EGFR 811/4885ERBB2 340/4885CHRNB2 4/4885 |
| US-20080214628-A1 | Compounds Capable of Activating Cholinergic Receptors | CHRNA4, CHRNB4, CHRM4 | EGFR 811/4885ERBB2 340/4885CHRNB2 4/4885 |
| US-20040214835-A1 | Compounds capable of activating cholinergic receptors | CHRNA4, CHRNB4, CHRM4 | EGFR 811/4885ERBB2 340/4885CHRNB2 4/4885 |
| US-20100121061-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | CHRM3, CHRM5, CHRM4 | EGFR 1706/4885ERBB2 1735/4885CHRNB2 14/4885 |
| US-20100160390-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | CHRNA4, CHRNB4, CHRM4 | EGFR 811/4885ERBB2 340/4885CHRNB2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.